| Nov 12 |
Theriva Biologics GAAP EPS of -$6.81
|
| Nov 12 |
Theriva Biologics: Q3 Earnings Snapshot
|
| Nov 1 |
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
|
| Oct 31 |
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
|
| Oct 3 |
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients
|
| Oct 3 |
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients
|
| Oct 3 |
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
|
| Sep 27 |
Theriva Biologics dips 11%, prices $2.5M equity offering
|
| Sep 27 |
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
|
| Sep 23 |
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
|
